Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PLD2 | O14939 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16108659 | 0.94 | PLD2 (0.44) | NPC1RAB9AMEN1KMT2APLD2 | |
| SCHEMBL14908414 | 0.94 | PLD2 (0.44) | NPC1RAB9AMEN1KMT2APLD2 | |
| SCHEMBL13941723 | 0.91 | NPC1 (0.48) | NPC1RAB9AMEN1KMT2APLD2 | |
| SCHEMBL16108752 | 0.87 | MAOA (0.54) | NPC1RAB9AMEN1KMT2APLD2 | |
| SCHEMBL13941522 | 0.87 | MAOA (0.54) | NPC1RAB9AMEN1KMT2APLD2 | |
| SCHEMBL13941508 | 0.87 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2APLD2 | |
| SCHEMBL16109349 | 0.87 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2APLD2 | |
| SCHEMBL13941381 | 0.86 | EGFR (0.52) | NPC1RAB9AMEN1KMT2APLD2 | |
| SCHEMBL16138544 | 0.85 | PLD2 (0.44) | NPC1RAB9AMEN1KMT2APLD2 | |
| SCHEMBL14908417 | 0.84 | POLB (0.49) | NPC1RAB9AMEN1KMT2APLD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278089-B2 | Method of treating HCV infection with a small molecule CHK2 inhibitor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140294767-A1 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | PROVID PHARMACEUTICALS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-8765802-B2 | Kinase inhibitors, compositions thereof, and methods of use therewith | PROVID PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765802-B2 | Kinase inhibitors, compositions thereof, and methods of use therewith | PROVID PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2155675-B1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS INC (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2013063462-A2 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. | 2009-01-15 | — | — | US | disclosed |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. | 2009-01-15 | — | — | US | disclosed |
| WO-2008156573-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294767-A1 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | CHEK2, CHEK1, CDK2 | NPC1 1491/4885RAB9A 1972/4885MEN1 3259/4885 |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | CHEK2, ATM, CHEK1 | NPC1 3750/4885RAB9A 2366/4885MEN1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.